Connect with us

Hi, what are you looking for?

Investing

Harmony Biosciences Shares Up 19% on Strong 3Q

Published

By Josh Beckerman

Harmony Biosciences shares rose 19% Tuesday as third-quarter net product revenue increased 37% on strong demand for narcolepsy drug Wakix and the company announced a $200 million stock-buyback program.

The stock was recently at $23.49 and is down about 57% this year.

Adjusted…

Read the full article here

In this article:
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

News

Disc Medicine, Inc. (IRON) Discusses ASH Conference Data Updates and Portfolio Progress Including Anemia and Iron Restriction Programs Transcript

Follow Play Earnings CallPlay Earnings Call Disc Medicine, Inc. (IRON) Discusses ASH Conference Data Updates and Portfolio Progress Including Anemia and Iron Restriction Programs...

6 days ago

Videos

Softbank sells entire stake in Nvidia, the health of the AI trade, flight cancellations mount

Watch full video on YouTube

5 days ago

Videos

Bill to end shutdown moves to House, CoreWeave cuts full-year sales outlook

Watch full video on YouTube

6 days ago

Videos

Why beef prices are out of control in the U.S.

Watch full video on YouTube

6 days ago